|
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) Évaluation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) Bundle
Vous cherchez à déterminer la valeur intrinsèque de Zhejiang Ausun Pharmaceutical Co., Ltd.? Notre calculatrice DCF (603229SS) intègre des données réelles ainsi que des fonctionnalités de personnalisation complètes, vous permettant d'affiner vos prévisions et de faire des choix d'investissement plus éclairés.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 307.9 | 409.2 | 569.7 | 764.5 | 816.8 | 1,047.8 | 1,344.2 | 1,724.4 | 2,212.2 | 2,838.0 |
| Revenue Growth, % | 0 | 32.91 | 39.21 | 34.2 | 6.83 | 28.29 | 28.29 | 28.29 | 28.29 | 28.29 |
| EBITDA | 86.0 | 122.5 | 191.3 | 296.9 | 339.6 | 360.2 | 462.1 | 592.8 | 760.5 | 975.6 |
| EBITDA, % | 27.95 | 29.94 | 33.58 | 38.83 | 41.58 | 34.38 | 34.38 | 34.38 | 34.38 | 34.38 |
| Depreciation | 22.7 | 25.4 | 30.0 | 34.5 | 40.6 | 59.4 | 76.2 | 97.8 | 125.4 | 160.9 |
| Depreciation, % | 7.38 | 6.21 | 5.27 | 4.51 | 4.97 | 5.67 | 5.67 | 5.67 | 5.67 | 5.67 |
| EBIT | 63.3 | 97.1 | 161.3 | 262.4 | 299.0 | 300.8 | 385.9 | 495.0 | 635.0 | 814.7 |
| EBIT, % | 20.56 | 23.73 | 28.31 | 34.32 | 36.61 | 28.71 | 28.71 | 28.71 | 28.71 | 28.71 |
| Total Cash | 342.1 | 739.1 | 674.6 | 612.9 | 1,124.2 | 1,006.2 | 1,290.9 | 1,656.0 | 2,124.4 | 2,725.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 62.4 | 45.6 | 66.2 | 134.8 | 135.6 | 161.9 | 207.7 | 266.4 | 341.8 | 438.5 |
| Account Receivables, % | 20.26 | 11.13 | 11.63 | 17.63 | 16.6 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 |
| Inventories | 187.9 | 190.2 | 243.4 | 320.6 | 365.2 | 496.4 | 636.8 | 816.9 | 1,048.0 | 1,344.5 |
| Inventories, % | 61.04 | 46.47 | 42.73 | 41.93 | 44.71 | 47.38 | 47.38 | 47.38 | 47.38 | 47.38 |
| Accounts Payable | 170.5 | 171.3 | 402.2 | 519.3 | 259.8 | 560.7 | 719.3 | 922.7 | 1,183.8 | 1,518.6 |
| Accounts Payable, % | 55.36 | 41.85 | 70.61 | 67.93 | 31.81 | 53.51 | 53.51 | 53.51 | 53.51 | 53.51 |
| Capital Expenditure | -49.6 | -93.0 | -310.9 | -271.9 | -163.5 | -312.2 | -400.5 | -513.8 | -659.1 | -845.6 |
| Capital Expenditure, % | -16.12 | -22.71 | -54.56 | -35.57 | -20.01 | -29.79 | -29.79 | -29.79 | -29.79 | -29.79 |
| Tax Rate, % | 12.68 | 12.68 | 12.68 | 12.68 | 12.68 | 12.68 | 12.68 | 12.68 | 12.68 | 12.68 |
| EBITAT | 58.9 | 88.3 | 147.7 | 241.4 | 261.1 | 273.6 | 351.0 | 450.3 | 577.7 | 741.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -47.8 | 36.1 | 23.9 | -24.7 | -166.6 | 164.2 | -.9 | -1.1 | -1.5 | -1.9 |
| WACC, % | 4.77 | 4.77 | 4.77 | 4.77 | 4.76 | 4.77 | 4.77 | 4.77 | 4.77 | 4.77 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 152.2 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -153 | |||||||||
| Present Terminal Value | -121 | |||||||||
| Enterprise Value | 31 | |||||||||
| Net Debt | -822 | |||||||||
| Equity Value | 853 | |||||||||
| Diluted Shares Outstanding, MM | 827 | |||||||||
| Equity Value Per Share | 1.03 |
What You Will Receive
- Authentic 603229SS Financial Data: Equipped with Zhejiang Ausun Pharmaceutical’s historical and projected financials for accurate analysis.
- Customizable Template: Adjust key parameters like revenue growth, WACC, and EBITDA % effortlessly.
- Instant Calculations: Watch the intrinsic value of Zhejiang Ausun Pharmaceutical update in real-time as you make changes.
- Expert Valuation Tool: Crafted for investors, analysts, and consultants aiming for precise DCF results.
- Intuitive Design: A straightforward layout and clear guidance suitable for all skill levels.
Key Features
- Advanced DCF Calculator: Features comprehensive unlevered and levered DCF valuation models tailored for Zhejiang Ausun Pharmaceutical Co., Ltd. (603229SS).
- WACC Calculator: Comes with a pre-constructed Weighted Average Cost of Capital sheet that allows for input customization.
- Editable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit specific projections.
- Built-In Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Zhejiang Ausun Pharmaceutical Co., Ltd. (603229SS).
- Dashboard and Charts: Graphical outputs provide a summary of essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Examine the pre-filled data on Zhejiang Ausun Pharmaceutical Co., Ltd. (603229SS) (historical and forecasted).
- Step 3: Modify key assumptions (highlighted in yellow) based on your analysis.
- Step 4: Observe the automatic recalculations reflecting the intrinsic value of Zhejiang Ausun Pharmaceutical Co., Ltd. (603229SS).
- Step 5: Utilize the results for investment decisions or reporting purposes.
Why Choose Zhejiang Ausun Pharmaceutical Co., Ltd. (603229SS)?
- Time Efficient: Instantly access a reliable platform without the need to build complex models from scratch.
- Enhanced Precision: Dependable financial data and calculations minimize valuation errors.
- Comprehensive Customization: Adjust the model to align with your specific assumptions and forecasts.
- User-Friendly Analysis: Intuitive charts and outputs facilitate straightforward interpretation of results.
- Expert Endorsement: Developed for professionals who prioritize accuracy and functionality.
Who Can Benefit from This Product?
- Pharmaceutical Students: Discover drug development processes and analyze them using real-world data.
- Researchers: Integrate industry-standard models into your studies or academic papers.
- Investors: Validate your investment strategies and assess valuation projections for Zhejiang Ausun Pharmaceutical Co., Ltd. (603229SS).
- Market Analysts: Enhance your analytical methods with a tailored, ready-to-use financial model.
- Healthcare Entrepreneurs: Understand the analytical frameworks used to evaluate major public companies like Zhejiang Ausun Pharmaceutical Co., Ltd. (603229SS).
What the Template Contains
- Historical Data: Comprises Zhejiang Ausun Pharmaceutical’s past financials and foundational forecasts.
- DCF and Levered DCF Models: Comprehensive templates for calculating the intrinsic value of Zhejiang Ausun Pharmaceutical.
- WACC Sheet: Pre-configured calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Adjust key variables such as growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: Thorough breakdown of Zhejiang Ausun Pharmaceutical’s financial performance.
- Interactive Dashboard: Dynamically visualize valuation outcomes and forecasts.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.